Nope.
Strike warrants & $100m. Funded for finishing mCRC through confirmation if choose.
While Spy returns TNBC / ICI data.
Cytodyn leverages ICI rights for a few upfront billions. Multiple Agreements if necessary.
Mfgr / production, training, govt interactions & maybe some operational, etc..
Cytodyn retains 100% iP & Sequencing LL & LAL dosing profits.
Cytodyn works deals around to in the end, all we do is Mfgr & ship. No need for Cytodyn to go top-heavy, in any way shape or form with what Leronlimab is achieving. We are not dependent on today's oncology industry, of 10m yearly deaths.
Patents on LL/LAL/ICI alone, could be leveraged for a book run from a major firm, funding any 3rd-party needs, if choose to.
Natera alone is major corp operational gaps, related to LL awareness, on Cytodyn's targeted population --- oncologist, surgeons, Medicare & the VA.
What we "need" from any pharma, we can easily leverage & fund to an amount, that is nowhere near, worth giving up chunks of CYDY / LL-LAL.
We are not an A-typical struggling, oh please "big" pharma, jump in.
They, are waiting for how & when, allowed to acces, our, 2nd Generation Immunotherapy Consortium
No pharma has anything Leronlimab "needs".
Paradim Shifts will not happen because of them